http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jingmin Xu (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Weibing Zhu,Jingmin Xu,Yingchun Li 한국지질과학협의회 2017 Geosciences Journal Vol.21 No.5
In Shendong coalfield, severe support failure accidents caused by the dynamic pressure occurred frequently when longwall faces extracting the lower coal seam progress below the chamber coal pillars. These incidents largely threaten the personnel safety and regular operations. The rationale of the dynamic pressure has been investigated based on the movement law of the overlying strata. Experimental and numerical simulations of a longwall face in Shigetai coal mine agree well with the qualitative explanations. It is shown that the failure of the chamber coal pillars causes the sudden break and even rotation of the key strata, thereby leading to strong dynamic load that crushes the supports in the longwall face. Several guidelines have been proposed to prevent the occurrence of the dynamic pressure, the capability of which has been demonstrated by in situ practice in two longwall faces in Shendong coalfield.
-
FLOW ANALYSIS AND THEORETICAL DESIGN OF DIESEL ENGINE EXHAUST PORT
Fushui Liu,Yang Xu,Jingmin Rui,Zhongjie Shi,Yikai Li 한국자동차공학회 2020 International journal of automotive technology Vol.21 No.1
Exhaust port is an important part of a diesel engine which affects the combustion and emission. It is important to have a good design for exhaust port. In this paper, the calculation formula of the optimal area ratio (Kopt) of outlet and inlet of exhaust port was derived. The formula shows that Kopt is only determined by relative pressure difference (RPD). Then influence of the area ratio (K) of outlet and inlet on flow capacity of exhaust port and the trend of Kopt with relative pressure difference were studied numerically to verify the validity and applicability of the formula. The numerical results shows that the mass flow rate increases first and then keeps constant with the increase of K at the same RPD. Kopt exists and decreases first and then keeps constant with the increase of RPD. The numerical trend is consistent with theoretical trend and the errors between maximum mass flow rates of numerical results and actual mass flow rates at theoretical optimal area ratios are all less than 5 % meeting engineering accuracy. It is indicated that the derived formula is correct and applicable. When an exhaust port is designed, the outlet area can be estimated by this formula.
-
Kuikui Jiang,Ruoxi Hong,Wen Xia,Qianyi Lu,Liang Li,Jianhao Huang,Yanxia Shi,Zhongyu Yuan,Qiufan Zheng,Xin An,Cong Xue,Jiajia Huang,Xiwen Bi,Meiting Chen,Jingmin Zhang,Fei Xu,Shusen Wang 대한암학회 2024 Cancer Research and Treatment Vol.56 No.2
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
